Chugai's osteoporosis agent Edirol launched in China

18 July 2022

Japanese drug major Chugai Pharmaceutical’s (TYO: 4519) Chinese subsidiary has launched Edirol (eldecalcitol) in China for the treatment of postmenopausal osteoporosis.

Edirol is an active vitamin D3 derivative created by Chugai. The product obtained regulatory approval from the China National Medical Products Administration (NMPA) on December 2020.

“We are very pleased that Edirol, an osteoporosis agent created by Chugai, has been launched in China. Edirol has long been recognized in Japan as a base drug for the treatment of osteoporosis, used by more than 10 million patients to date,” said Dr Osamu Okuda, president and chief executive of Chugai, which is majority-owned by Switzerland’s Roche (ROG: SIX). “Prevention of fractures is important for the well-being of patients with osteoporosis. Aiming to contribute to the osteoporosis treatment in China, Chugai Pharma China, a group company which leads our business in China, will provide information of Edirol in collaboration with Roche China,” he added

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK